NCT00615524View on ClinicalTrials.gov

Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2008

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Hormone-receptor Positive Breast Cancer
Interventions
DRUG

exemestane and pazopanib

Trial Locations (1)

94115

GSK Clinical Trials Call Center, San Francisco

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00615524 - Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer | Biotech Hunter | Biotech Hunter